Lumenis announced today its support for the creation of World Head and Neck Cancer Day
Lumenis Ltd. (NASDAQ: LMNS), the world’s largest medical energy-based solutions company for surgical, ophthalmology and aesthetic applications, announced today its support for the creation of World Head and Neck Cancer Day. The online petition to declare July 27 as World Head and Neck Cancer Day can be found at www.ahns2014.org/petition.
Head Neck Squamous Cell Carcinoma (HNSCC) is the leading cause of death and disability in most parts of the world. The vast majority of HNSCC can be prevented or cured if detected early, but millions of people suffer from delayed diagnosis, inadequate treatment and inappropriate rehabilitation and palliation. To address the global challenge of HNSCC, the World Head and Neck Cancer Day petition calls for a multi-sectoral response from governments, non-government organizations, health care professionals, civil society, academia and industry.
” Improving public awareness of head and neck cancer can help save lives by encouraging earlier diagnosis and treatment,” said Tzipi Ozer-Armon, Chief Executive Officer of Lumenis. “Lumenis is proud to support the creation of World Head and Neck Cancer Day and remains committed to advancing patient education and clinical care in partnership with the HNSCC community.”
Lumenis recently introduced Throat-Cancer.com, an educational website for patients. Visitors to the site can find disease information, an overview of surgical treatment options and videos with medical experts and patients sharing their insights about the condition.
Lumenis (NASDAQ: LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare.
For more information visit: www.lumenis.com
Information provided in this release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company’s plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “plan,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon management’s current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and Lumenis undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Lazar Partners Ltd.